BRAF and melanoma: Here, we could not only confirm that YB-1 is an important target of the MAPK/RSK signalling axis in malignant melanoma, but also show, that vemurafenib resistant melanoma cells can be re-sensitised towards long-term exposure with the BRAF inhibitor by YB-1 knockdown.